Identification of negative regulatory regions within the first exon and intron of the BCL6 gene - PubMed (original) (raw)

Comparative Study

. 2000 Oct 5;19(42):4941-5.

doi: 10.1038/sj.onc.1203864.

Affiliations

• PMID: 11039912
• DOI: 10.1038/sj.onc.1203864

Comparative Study

Identification of negative regulatory regions within the first exon and intron of the BCL6 gene

M Kikuchi et al. Oncogene. 2000.

Abstract

Chromosomal translocations involving BCL6 gene are frequent in human B-cell lymphomas. Chromosomal breaks preferentially occur within a 3-kb region containing the first exon and intron. Recent reports have revealed that internal deletions or point mutations also are common in this region, suggesting that structural alteration of this region may be a crucial event in the development of lymphomas. In this study, we identified two regions in the BCL6 gene that negatively regulate BCL6 expression. One region, ES, is located within the first exon between nucleotides +472 and +543, and a second region, IS, is located between +783 and + 918 of the first intron. A consensus nucleotide sequence for the binding of the BCL6 protein itself was found within the ES region. An electrophoretic mobility shift assay and a co-transfection experiment using a BCL6 expression vector showed that transcription of the BCL6 gene was negatively regulated by the BCL6 gene product. The IS region which is included in the regions commonly deleted in B-cell lymphomas had a silencer activity. Structural alterations of these two regions may play roles in the deregulated expression of the BCL6 gene in B-cell lymphomas.

PubMed Disclaimer

Similar articles

• The gene for interleukin-21 receptor is the partner of BCL6 in t(3;16)(q27;p11), which is recurrently observed in diffuse large B-cell lymphoma.
  Ueda C, Akasaka T, Kurata M, Maesako Y, Nishikori M, Ichinohasama R, Imada K, Uchiyama T, Ohno H. Ueda C, et al. Oncogene. 2002 Jan 17;21(3):368-76. doi: 10.1038/sj.onc.1205099. Oncogene. 2002. PMID: 11821949
• Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma.
  Chaganti SR, Chen W, Parsa N, Offit K, Louie DC, Dalla-Favera R, Chaganti RS. Chaganti SR, et al. Genes Chromosomes Cancer. 1998 Dec;23(4):323-7. Genes Chromosomes Cancer. 1998. PMID: 9824205
• Identification of heterologous translocation partner genes fused to the BCL6 gene in diffuse large B-cell lymphomas: 5'-RACE and LA - PCR analyses of biopsy samples.
  Yoshida S, Kaneita Y, Aoki Y, Seto M, Mori S, Moriyama M. Yoshida S, et al. Oncogene. 1999 Dec 23;18(56):7994-9. doi: 10.1038/sj.onc.1203293. Oncogene. 1999. PMID: 10637510
• Targeted somatic mutation of the BCL6 proto-oncogene and its impact on lymphomagenesis.
  Jardin F, Sahota SS. Jardin F, et al. Hematology. 2005 Apr;10(2):115-29. doi: 10.1080/10245330400026105. Hematology. 2005. PMID: 16019457 Review.
• BCL-6 in diffuse large-cell lymphomas.
  Dalla-Favera R, Ye BH, Cattoretti G, Lo Coco F, Chang CC, Zhang J, Migliazza A, Cechova K, Niu H, Chaganti S, Chen W, Louie DC, Offit K, Chaganti RS. Dalla-Favera R, et al. Important Adv Oncol. 1996:139-48. Important Adv Oncol. 1996. PMID: 8791133 Review. No abstract available.

Cited by

• TRAF3-EWSR1 signaling axis acts as a checkpoint on germinal center responses.
  Li Y, Zhu L, Ko CJ, Yang JY, Wang H, Manyam G, Wang J, Cheng X, Zhao S, Jie Z. Li Y, et al. J Exp Med. 2023 Aug 7;220(8):e20221483. doi: 10.1084/jem.20221483. Epub 2023 Apr 25. J Exp Med. 2023. PMID: 37097293 Free PMC article.
• The oncoprotein BCL6 enables solid tumor cells to evade genotoxic stress.
  Liu Y, Feng J, Yuan K, Wu Z, Hu L, Lu Y, Li K, Guo J, Chen J, Ma C, Pang X. Liu Y, et al. Elife. 2022 May 3;11:e69255. doi: 10.7554/eLife.69255. Elife. 2022. PMID: 35503721 Free PMC article.
• BCL6 confers KRAS-mutant non-small-cell lung cancer resistance to BET inhibitors.
  Guo J, Liu Y, Lv J, Zou B, Chen Z, Li K, Feng J, Cai Z, Wei L, Liu M, Pang X. Guo J, et al. J Clin Invest. 2021 Jan 4;131(1):e133090. doi: 10.1172/JCI133090. J Clin Invest. 2021. PMID: 33393503 Free PMC article.
• Suppression of Inflammasome Activation by IRF8 and IRF4 in cDCs Is Critical for T Cell Priming.
  McDaniel MM, Kottyan LC, Singh H, Pasare C. McDaniel MM, et al. Cell Rep. 2020 May 5;31(5):107604. doi: 10.1016/j.celrep.2020.107604. Cell Rep. 2020. PMID: 32375053 Free PMC article.
• Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells.
  Cortiguera MG, García-Gaipo L, Wagner SD, León J, Batlle-López A, Delgado MD. Cortiguera MG, et al. Sci Rep. 2019 Nov 11;9(1):16495. doi: 10.1038/s41598-019-52714-4. Sci Rep. 2019. PMID: 31712669 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group